Supporting your practice: Compounding sodium benzoate oral liquid for urea cycle disorders

No Thumbnail Available
File version
Author(s)
Haywood, Alison
Glass, Beverley
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2021
Size
File type(s)
Location
License
Abstract

Urea cycle disorders (UCD) are rare inherited metabolic disorders with an incidence estimated to be 1: 35,000 births. UCDs are caused by the dysfunction of any of the six enzymes (namely, carbamoyl phosphate synthetase I, N-acetylglutamate synthetase, ornithine transcarbamylase, argininosuccinic acid synthetase, argininosuccinate lyase, and arginase) or the two transport proteins (ornithine translocase and aspartate/glutamate carrier) involved in urea biosynthesis. The urea cycle converts the highly toxic ammonia produced from amino acid catabolism into urea, for excretion via the kidneys. A defect in urea synthesis results in hyperammonemia.

Journal Title

Australian Pharmacist

Conference Title
Book Title
Edition
Volume

40

Issue

8

Thesis Type
Degree Program
School
DOI
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Pharmaceutical sciences

Pharmacology and pharmaceutical sciences

Persistent link to this record
Citation

Haywood, A; Glass, B, Supporting your practice: Compounding sodium benzoate oral liquid for urea cycle disorders, Australian Pharmacist, 2021, 40 (8), pp. 54-61

Collections